Hasenclever IPS Calculator

Hasenclever IPS Calculator for Hematology. The score is the count of adverse factors and maps directly to 5-year freedom from progression in the derivation cohort: 0 factors approximately 84%, 1 approximately 77%, 2 approximately 67%, 3 approximately 60%, 4 approximately 51%, and 5 or more approximately 42%, with each additional point subtracting roughly 7-8 percentage points. Scores of 0-2 identify lower-risk patients often managed with standard ABVD, while scores of 4 or more mark higher-risk disease historically considered for treatment intensification. Notably, the authors could not isolate a distinct very-high-risk subgroup, so no single cutoff reliably identifies patients destined to fail standard therapy. In modern practice IPS refines the pretreatment estimate but is increasingly used alongside, not instead of, interim PET-adapted strategies.

How this calculator works

The International Prognostic Score (IPS) counts how many of seven adverse baseline features are present at diagnosis in advanced-stage Hodgkin lymphoma, each carrying equal weight of one point (range 0-7). The seven factors are serum albumin below 4 g/dL, hemoglobin below 10.5 g/dL, male sex, age 45 years or older, Ann Arbor stage IV disease, leukocytosis (white-cell count at least 15,000/mm3), and lymphocytopenia (lymphocyte count below 600/mm3, below 8% of the white-cell count, or both). The total is a simple unweighted sum derived from a Cox model on 1,618 patients, calibrated against 5-year freedom from progression (FFP) and overall survival.

When to use this calculator

Apply the IPS at diagnosis in adults with advanced-stage classical Hodgkin lymphoma, operationally Ann Arbor stage III-IV or bulky/B-symptomatic stage II treated with combination chemotherapy such as ABVD or escalated BEACOPP. It is a group-level risk stratifier for trial design and treatment-intensity discussions, not a validated tool for early-stage (I-II favorable) disease, nodular lymphocyte-predominant Hodgkin lymphoma, pediatric patients, or non-Hodgkin lymphomas. It also does not incorporate interim PET response, which now drives most contemporary treatment adaptation.

Inputs used

Albumin
Hemoglobin
Sex
Stage
Age
White blood cell count
Lymphocyte count

Clinical interpretation

The score is the count of adverse factors and maps directly to 5-year freedom from progression in the derivation cohort: 0 factors approximately 84%, 1 approximately 77%, 2 approximately 67%, 3 approximately 60%, 4 approximately 51%, and 5 or more approximately 42%, with each additional point subtracting roughly 7-8 percentage points. Scores of 0-2 identify lower-risk patients often managed with standard ABVD, while scores of 4 or more mark higher-risk disease historically considered for treatment intensification. Notably, the authors could not isolate a distinct very-high-risk subgroup, so no single cutoff reliably identifies patients destined to fail standard therapy. In modern practice IPS refines the pretreatment estimate but is increasingly used alongside, not instead of, interim PET-adapted strategies.

Worked example

A 52-year-old man presents with stage IV classical Hodgkin lymphoma, albumin 3.4 g/dL, hemoglobin 11.8 g/dL, WBC 12,000/mm3, and absolute lymphocyte count 900/mm3. He scores points for male sex, age 45 or older, stage IV, and low albumin, while hemoglobin, leukocytosis, and lymphocytopenia are not met, giving IPS = 4. In the original cohort this predicted roughly 51% 5-year freedom from progression, placing him in a higher-risk band that would prompt discussion of intensified therapy and close interim PET monitoring.

Limitations and safety notes

The IPS was derived in the 1980s-early 1990s before PET staging and modern regimens, so outcome estimates now understate cure rates and its discrimination has attenuated in contemporary cohorts, where the spread between best and worst bands has narrowed. Because factors are unweighted, clinically dissimilar patients can share a score, and the model performs poorly at the extremes given how few patients fall at scores of 0 or 5 or higher. It ignores tumor bulk, interim PET response, and biology, and should not be applied to early-stage disease, NLPHL, children, or as a standalone reason to escalate therapy in an otherwise good interim-PET responder.

Frequently asked questions

Does a low IPS mean I can safely de-escalate treatment?

Not by itself. A low IPS (0-2) signals favorable baseline risk, but de-escalation decisions in current practice hinge chiefly on interim PET response after 2 cycles rather than IPS alone. The score informs the conversation but is not a validated de-escalation trigger.

Is the IPS still relevant now that PET-adapted therapy is standard?

Yes, as a baseline stratifier and for trial stratification, but its prognostic separation is weaker than in 1998 because overall outcomes have improved. Many centers now report a modified 3-group version (0-1, 2-3, 4 or higher) and pair it with interim PET, which carries stronger independent prognostic weight.

How do I handle lymphocytopenia if I only have a differential percentage?

The criterion is met if the absolute lymphocyte count is below 600/mm3 OR lymphocytes are below 8% of the total white-cell count, or both. Either condition alone counts as one point, so a normal absolute count with a very low percentage still scores.

Why is the albumin cutoff 4 g/dL rather than the usual lower-normal limit?

The 4 g/dL threshold was empirically derived from the Cox model, not from a laboratory normal range. Low albumin captures tumor burden and inflammatory state, and at this cutoff it was one of the strongest independent adverse factors in the original analysis.

Can I use IPS for early-stage Hodgkin lymphoma?

No. The IPS was built and validated only in advanced-stage disease treated with combination chemotherapy. Early-stage risk stratification uses separate criteria (such as GHSG or EORTC unfavorable factors), and applying IPS there is off-label and unvalidated.

References

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998. PMID: 9819449.
Brosteanu O, Hasenclever D, Loeffler M, Diehl V. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol. 2003. PMID: 15064867.

Editorial review and citation methodology

Reviewed by the Quick Medical Calculator Editorial Team. Last reviewed: May 10, 2026. The review checks calculator inputs, intended population, interpretation, limitations, and source alignment.

Prefer original validation studies for scoring systems and prediction tools.
Use current specialty society guidance, transplant allocation policy, public health guidance, or regulator resources when they govern clinical use.
Include limitations and safety notes when a calculator is population-specific, context-dependent, or unsuitable as a standalone decision tool.